Regeneron Pharmaceuticals, Inc. โ NASDAQ:REGN
Founder-led company
Regeneron Pharmaceuticals stock price today
$574.79
-137.61
-19.32%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 3 hours
Regeneron Pharmaceuticals stock price monthly change
-35.24%
month
Regeneron Pharmaceuticals stock price quarterly change
-35.24%
quarter
Regeneron Pharmaceuticals stock price yearly change
-18.52%
year
Regeneron Pharmaceuticals key metrics
Market Cap | 76.96B |
Enterprise value | 88.01B |
P/E | 21.36 |
EV/Sales | 7.23 |
EV/EBITDA | 16.73 |
Price/Sales | 7.20 |
Price/Book | 3.86 |
PEG ratio | -0.45 |
EPS | 36.11 |
Revenue | 13.10B |
EBITDA | 4.45B |
Income | 3.85B |
Revenue Q/Q | -0.54% |
Revenue Y/Y | 5.90% |
Profit margin | 35.64% |
Oper. margin | 39.18% |
Gross margin | 87.18% |
EBIT margin | 39.18% |
EBITDA margin | 33.99% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want toย keep trackย of and getย notified inย theย smart feed every time fresh news arrives.
Sign up for freeRegeneron Pharmaceuticals stock price history
Regeneron Pharmaceuticals stock forecast
Regeneron Pharmaceuticals financial statements
Average Price Target
$1,153.31
Potential upside: 100.64%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 3.15B | 968.4M | 30.66% |
|---|---|---|---|
| Sep 2023 | 3.36B | 1.00B | 29.97% |
| Dec 2023 | 3.43B | 1.15B | 33.77% |
| Mar 2024 | 3.14B | 722M | 22.96% |
| Jun 2023 | 30657500000 | 6.63B | 21.66% |
|---|---|---|---|
| Sep 2023 | 32163300000 | 7.25B | 22.57% |
| Dec 2023 | 33080200000 | 7.10B | 21.48% |
| Mar 2024 | 34369600000 | 7.37B | 21.47% |
| Jun 2023 | 1.02B | -2.38B | -614.2M |
|---|---|---|---|
| Sep 2023 | 1.11B | -496.3M | -407.3M |
| Dec 2023 | 1.08B | -66.2M | -446.1M |
| Mar 2024 | 1.51B | -1.68B | 47.1M |
Regeneron Pharmaceuticals alternative data
Regeneron Pharmaceuticals Social Media Accounts
What are followers?
+0.54%
month
| May 2025 | 14836 |
|---|---|
| Jul 2025 | 16455 |
| Aug 2025 | 16544 |
Areas of Focus
| 12 Feb 2023 | 2 | 0 | 1 | 28 | 9 |
|---|---|---|---|---|---|
| 19 Feb 2023 | 2 | 0 | 1 | 30 | 10 |
| 26 Feb 2023 | 2 | 0 | 1 | 29 | 10 |
| 5 Mar 2023 | 2 | 0 | 1 | 30 | 11 |
| 12 Mar 2023 | 2 | 0 | 1 | 32 | 10 |
| 19 Mar 2023 | 3 | 0 | 1 | 33 | 10 |
| 26 Mar 2023 | 2 | 0 | 1 | 29 | 10 |
| 2 Apr 2023 | 3 | 0 | 1 | 30 | 11 |
| 9 Apr 2023 | 2 | 0 | 1 | 30 | 10 |
| 16 Apr 2023 | 3 | 0 | 1 | 30 | 10 |
| 23 Apr 2023 | 2 | 0 | 1 | 28 | 10 |
| 30 Apr 2023 | 2 | 0 | 1 | 27 | 9 |
| 7 May 2023 | 2 | 0 | 1 | 31 | 10 |
| 14 May 2023 | 2 | 0 | 1 | 31 | 10 |
| 21 May 2023 | 2 | 0 | 1 | 26 | 9 |
| 28 May 2023 | 2 | 0 | 1 | 30 | 9 |
| 4 Jun 2023 | 2 | 0 | 1 | 27 | 10 |
| 11 Jun 2023 | 2 | 0 | 1 | 28 | 9 |
| 18 Jun 2023 | 2 | 0 | 1 | 24 | 8 |
| 25 Jun 2023 | 2 | 0 | 1 | 27 | 8 |
Regeneron Products
| 12 Feb 2023 | 24 | 1 | 0 | 7 | 7 |
|---|---|---|---|---|---|
| 19 Feb 2023 | 23 | 4 | 0 | 7 | 6 |
| 26 Feb 2023 | 21 | 0 | 0 | 20 | 5 |
| 5 Mar 2023 | 20 | 0 | 0 | 8 | 5 |
| 12 Mar 2023 | 25 | 1 | 0 | 7 | 8 |
| 19 Mar 2023 | 28 | 0 | 0 | 6 | 9 |
| 26 Mar 2023 | 28 | 1 | 0 | 6 | 3 |
| 2 Apr 2023 | 24 | 0 | 0 | 8 | 9 |
| 9 Apr 2023 | 29 | 0 | 0 | 6 | 6 |
| 16 Apr 2023 | 22 | 0 | 2 | 6 | 7 |
| 23 Apr 2023 | 22 | 0 | 0 | 4 | 6 |
| 30 Apr 2023 | 21 | 0 | 0 | 6 | 4 |
| 7 May 2023 | 25 | 0 | 0 | 9 | 4 |
| 14 May 2023 | 33 | 0 | 0 | 6 | 4 |
| 21 May 2023 | 19 | 1 | 3 | 7 | 8 |
| 28 May 2023 | 22 | 4 | 0 | 9 | 6 |
| 4 Jun 2023 | 26 | 0 | 0 | 8 | 6 |
| 11 Jun 2023 | 35 | 0 | 0 | 6 | 7 |
| 18 Jun 2023 | 15 | 0 | 0 | 8 | 3 |
| 25 Jun 2023 | 19 | 0 | 0 | 4 | 3 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Sep 2023 | 482 |
|---|---|
| Oct 2023 | 408 |
| Nov 2023 | 453 |
| Dec 2023 | 372 |
| Jan 2024 | 386 |
| Feb 2024 | 522 |
| Apr 2024 | 435 |
| May 2024 | 394 |
| Jun 2024 | 468 |
| Jul 2024 | 431 |
| Dec 2024 | 394 |
| Sep 2023 | 12,256 |
|---|---|
| Oct 2023 | 12,256 |
| Nov 2023 | 12,256 |
| Dec 2023 | 12,463 |
| Jan 2024 | 12,463 |
| Feb 2024 | 12,463 |
| Mar 2024 | 13,450 |
| Apr 2024 | 13,450 |
| May 2024 | 13,450 |
| Jun 2024 | 13,677 |
| Jul 2024 | 13,677 |
Regeneron Pharmaceuticals other data
81.29%
+2.24%
of REGN is owned by hedgeย funds
1.04K
-1
91.20M
+1.17M
shares is hold by hedgeย funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 13843 |
| Feb 2024 | 0 | 2000 |
| Mar 2024 | 0 | 6241 |
| Apr 2024 | 0 | 350 |
| May 2024 | 0 | 159121 |
| Aug 2024 | 0 | 18295 |
| Sep 2024 | 0 | 1100 |
| Oct 2024 | 0 | 1100 |
| Nov 2024 | 0 | 1000 |
| Patent |
|---|
Grant Filling date: 8 May 2020 Issue date: 27 Sep 2022 |
Grant Filling date: 18 Dec 2019 Issue date: 27 Sep 2022 |
Grant Filling date: 24 Oct 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 10 Jul 2019 Issue date: 20 Sep 2022 |
Grant Filling date: 16 Jul 2021 Issue date: 13 Sep 2022 |
Grant Filling date: 22 Jun 2021 Issue date: 13 Sep 2022 |
Grant Filling date: 21 Nov 2019 Issue date: 13 Sep 2022 |
Grant Filling date: 31 Mar 2021 Issue date: 6 Sep 2022 |
Grant Filling date: 17 Dec 2020 Issue date: 6 Sep 2022 |
Grant Filling date: 17 Dec 2019 Issue date: 6 Sep 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 2 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
Eli Lilly Comes Out As ADA Winner
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast
Amgen: Imdelltra Data And Q1 Results Impress
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC
-
What's the price of Regeneron Pharmaceuticals stock today?
One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $574.79.
-
When is Regeneron Pharmaceuticals's next earnings date?
Unfortunately, Regeneron Pharmaceuticals's (REGN) next earnings date is currently unknown.
-
Does Regeneron Pharmaceuticals pay dividends?
No, Regeneron Pharmaceuticals does not pay dividends.
-
How much money does Regeneron Pharmaceuticals make?
Regeneron Pharmaceuticals has a market capitalization of 76.96B and it's past yearsโ income statements indicate that its last revenue has increased compared to the previous period by 7.76% to 13.12B US dollars.
-
What is Regeneron Pharmaceuticals's stock symbol?
Regeneron Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "REGN".
-
What is Regeneron Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Regeneron Pharmaceuticals?
Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Regeneron Pharmaceuticals's key executives?
Regeneron Pharmaceuticals's management team includes the following people:
- Dr. Leonard S. Schleifer Co-Founder, Pres, Chief Executive Officer & Executive Director(age: 72, pay: $5,350,000)
- Dr. George D. Yancopoulos Scientific Founder, Pres, Chief Scientific Officer & Director(age: 65, pay: $4,380,000)
- Mr. Robert E. Landry Jr. Executive Vice President of Fin. & Chief Financial Officer(age: 61, pay: $1,790,000)
- Mr. Daniel P. Van Plew Executive Vice President and GM of Industrial Operations & Product Supply(age: 52, pay: $1,790,000)
- Dr. Andrew J. Murphy Executive Vice President of Research(age: 67, pay: $1,640,000)
-
Is Regeneron Pharmaceuticals founder-led company?
Yes, Regeneron Pharmaceuticals is a company led by its founders Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos.
-
How many employees does Regeneron Pharmaceuticals have?
As Jul 2024, Regeneron Pharmaceuticals employs 13,677 workers, which is 2% more then previous quarter.
-
When Regeneron Pharmaceuticals went public?
Regeneron Pharmaceuticals, Inc. is publicly traded company for more then 34 years since IPO on 2 Apr 1991.
-
What is Regeneron Pharmaceuticals's official website?
The official website for Regeneron Pharmaceuticals is regeneron.com.
-
Where are Regeneron Pharmaceuticals's headquarters?
Regeneron Pharmaceuticals is headquartered at 777 Old Saw Mill River Road, Tarrytown, NY.
-
How can i contact Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals's mailing address is 777 Old Saw Mill River Road, Tarrytown, NY and company can be reached via phone at +91 48477000.
-
What is Regeneron Pharmaceuticals stock forecast & price target?
Based on 11 Wall Street analysts` predicted price targets for Regeneron Pharmaceuticals in the last 12 months, the avarage price target is $1,153.31. The average price target represents a 100.64% change from the last price of $574.79.
Regeneron Pharmaceuticals company profile:
Regeneron Pharmaceuticals, Inc.
regeneron.comExchange:
NASDAQ
Full time employees:
14,165
Industry:
Biotechnology
Sector:
Healthcare
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Tarrytown, NY 10591-6707
CIK: 0000872589
ISIN: US75886F1075
CUSIP: 75886F107
